Saturday 17 October 2026
Export SCYX’s income statement to Excel — free account
SCYNEXIS, Inc.
SCYX Healthcare Drug Manufacturers Specialty & Generic
SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.67
0.24
−6.14%
Follow SCYX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.34 | — | 1.53 | 13.10 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(3.23) | — | 1.72 | (4.40) | |
P/B ratio |
0.72 | — | 0.64 | 1.05 | |
Price to Tangible BV |
0.72 | — | 0.64 | 1.06 | |
EV/Sales |
0.96 | — | 0.84 | 8.96 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(1.49) | — | (3.28) | (0.78) | |
EV/FCF |
(1.49) | — | (3.27) | (0.78) | |
Quick Ratio |
9.30 | 3.73 | 7.00 | 4.49 | |
Current Ratio |
9.65 | 3.94 | 7.04 | 5.75 | |
Net Debt/EBITDA |
6.97 | 3.50 | (3.82) | 4.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.30 | 0.00 | 0.28 | 0.04 | |
Operating CF/Net income |
(2.01) | 0.38 | 1.50 | 1.02 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,655.74% | 0.00% | 24.38% | 1,632.34% | |
Selling, General and Administrative Expense of Revenue |
1,752.77% | 0.00% | 19.30% | 984.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
241.70% | 0.00% | 3.68% | 157.49% | |
Graham Net Nets |
1.00 | — | 0.97 | 0.89 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(51.35%) | — | (26.88%) | (66.23%) | |
Free Cash Flow Yield |
(27.69%) | — | (16.78%) | (87.47%) | |
Revenue per Share |
0.02 | 0.00 | 2.99 | 0.05 | |
Operating CF per Share |
(1.26) | (1.27) | 2.95 | (1.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.26) | (1.27) | 2.95 | (1.40) | |
Cash per Share |
4.58 | 9.32 | 6.43 | 6.09 | |
Shareholders Equity per Share |
5.66 | 6.49 | 7.91 | 5.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.66 | 6.49 | 7.91 | 5.84 | |
Free Cash Flow |
(14.88) | (8.10) | 18.40 | (8.72) | |
Working Capital |
50.41 | 46.79 | 34.64 | 40.23 | |
Net Current Asset Value |
48.20 | 26.37 | 30.72 | 34.05 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.72 | 4.95 | 3.40 | 4.21 | |
Average Assets |
67.83 | 72.77 | 74.84 | 75.05 | |
Average Common Equity |
55.70 | 45.92 | 52.23 | 47.48 |
Columns are period end dates